{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:33:46Z","timestamp":1781343226780,"version":"3.54.1"},"reference-count":98,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Huntington\u2019s Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities. The disorder is a result of a trinucleotide repeat expansion mutation that is inherited in an autosomal dominant manner. While there is currently no treatment to alter the course of HD, there are medications that lessen abnormal movement and psychiatric symptoms. ClinicalTrials.gov was searched to identify drugs that are currently in or have completed phase III drug trials for the treatment of HD. The described phase III trials were further limited to interventional studies that were recruiting, active not recruiting, or completed. In addition, all studies must have posted an update within the past year. PubMed was used to gather further information on these interventional studies. Of the nine clinical trials that met these criteria, eight involved the following drugs: metformin, dextromethorphan\/quinidine, deutetrabenazine, valbenazine, Cellavita HD, pridopidine, SAGE-718, and RO7234292 (RG6042). Of these drug treatments, four are already FDA approved. This systematic review provides a resource that summarizes the present therapies for treating this devastating condition that are currently in phase III clinical trials in the United States.<\/jats:p>","DOI":"10.3390\/ph16111513","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:34:47Z","timestamp":1698147287000},"page":"1513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Huntington\u2019s Disease Drug Development: A Phase 3 Pipeline Analysis"],"prefix":"10.3390","volume":"16","author":[{"given":"Hannah J.","family":"Van de Roovaart","sequence":"first","affiliation":[{"name":"School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2941-0225","authenticated-orcid":false,"given":"Timothy D.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JHD-200404","article-title":"The clinical features and progression of late-onset versus younger-onset in an adult cohort of Huntington\u2019s Disease patients","volume":"9","author":"Anil","year":"2020","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/ene.15645","article-title":"Economic burden of Huntington disease in Europe and the USA: Results from the Huntington\u2019s Disease Burden of Illness study","volume":"30","author":"Mestre","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/13696998.2022.2033493","article-title":"Epidemiology and economic burden of Huntington\u2019s disease: A Canadian provincial public health system perspective","volume":"1","author":"Shaw","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","article-title":"Huntington\u2019s disease genetics","volume":"1","author":"Myers","year":"2004","journal-title":"NeuroRx"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2022.02.022","article-title":"Huntington\u2019s disease influences employment before and during clinical manifestation: A systematic review","volume":"96","author":"Mentink","year":"2022","journal-title":"Park. Relat. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","article-title":"Interrupting sequence variants and age of onset in Huntington\u2019s disease: Clinical implications and emerging therapies","volume":"19","author":"Wright","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0896-6273(93)90127-D","article-title":"Huntington\u2019s disease gene (IT15) is widely expressed in human and rat tissues","volume":"11","author":"Li","year":"1993","journal-title":"Neuron"},{"key":"ref_11","first-page":"65","article-title":"The biological function of the Huntingtin protein and its relevance to Huntington\u2019s Disease pathology","volume":"5","author":"Schulte","year":"2011","journal-title":"Curr. Trends Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1098\/rstb.1999.0457","article-title":"Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington\u2019s disease in cell culture and in transgenic mice expressing mutant huntingtin","volume":"354","author":"Hackam","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and Neuropathology of Huntington\u2019s Disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/302374","article-title":"A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease","volume":"64","author":"Almqvist","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddy119","article-title":"A whole brain longitudinal study in the YAC128 mouse model of Huntington\u2019s disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes","volume":"27","author":"Petrella","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnins.2020.00082","article-title":"Cortical and striatal circuits in Huntington\u2019s disease","volume":"14","author":"Blumenstock","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1242929","DOI":"10.3389\/fnsys.2023.1242929","article-title":"Basal ganglia for beginners: The basic concepts you need to know and their role in movement control","volume":"17","author":"Rocha","year":"2023","journal-title":"Front. Syst. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington\u2019s disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1007\/s10072-021-05527-1","article-title":"Deep brain stimulation in Huntington\u2019s disease: A literature review","volume":"42","author":"Bonomo","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/NRL.0b013e31815b0de2","article-title":"Frontal-subcortical dementias","volume":"14","author":"Bonelli","year":"2008","journal-title":"Neurologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1007\/s00415-022-11551-8","article-title":"Quality of life, health-related quality of life, and associated factors in Huntington\u2019s disease: A systematic review","volume":"270","author":"Frank","year":"2023","journal-title":"J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19642","DOI":"10.1038\/s41598-022-21900-2","article-title":"Fragment-based virtual screening identifies a first-in class preclinical drug for Huntington\u2019s disease","volume":"12","author":"Galyan","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_25","unstructured":"(2023, September 12). Huntington\u2019s Disease. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/huntingtons-disease\/diagnosis-treatment\/drc-20356122."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/JHD-229006","article-title":"Huntington\u2019s Disease clinical trials corner: November 2022","volume":"11","author":"Tabrizi","year":"2022","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_27","first-page":"11","article-title":"Management of type 2 diabetes: Update on new pharmacological options","volume":"9","author":"Blonde","year":"2000","journal-title":"Manag. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40262-015-0323-x","article-title":"Therapeutic concentrations of metformin: A systematic review","volume":"55","author":"Kajbaf","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"865524","DOI":"10.3389\/fphar.2022.865524","article-title":"The function of metformin in aging-related musculoskeletal disorders","volume":"13","author":"Song","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111670","DOI":"10.1016\/j.mad.2022.111670","article-title":"Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder","volume":"204","author":"Herrero","year":"2022","journal-title":"Mech. Ageing Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10911-019-09429-z","article-title":"Metformin and breast cancer: Molecular targets","volume":"24","author":"Faria","year":"2019","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-4159.2009.05916.x","article-title":"AMPK in the brain: Its roles in energy balance and neuroprotection","volume":"109","author":"Ronnett","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0264-9","article-title":"Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease","volume":"51","author":"Sanchis","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Herv\u00e1s, D., Forn\u00e9s-Ferrer, V., G\u00f3mez-Escribano, A.P., Sequedo, M.D., Peir\u00f3, C., Mill\u00e1n, J.M., and V\u00e1zquez-Manrique, R.P. (2017). Metformin intake associates with better cognitive function in patients with Huntington\u2019s disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179283"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/156720512799015064","article-title":"Metabolic dysfunction in Alzheimer\u2019s disease and related neurodegenerative disorders","volume":"9","author":"Cai","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102448","DOI":"10.1016\/j.pneurobio.2023.102448","article-title":"PolyQ length-dependent metabolic alterations and DNA damage drive human astrocyte dysfunction in Huntington\u2019s disease","volume":"225","author":"Lange","year":"2023","journal-title":"Prog. Neurobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2174\/1570159X20666220830112408","article-title":"Mitochondrial medicine: A promising therapeutic option against various neurodegenerative disorders","volume":"21","author":"Almikhlafi","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cns.12837","article-title":"Altered lactate metabolism in Huntington\u2019s disease is dependent on GLUT3 expression","volume":"24","author":"Loaiza","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3233\/JAD-160841","article-title":"Glucose transporters in brain: In health and in Alzheimer\u2019s disease","volume":"55","author":"Szablewski","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chaves, G., Stanley, J., and Pourmand, N. (2019). Mutant huntingtin affects diabetes and Alzheimer\u2019s markers in human and cell models of Huntington\u2019s Disease. Cells, 8.","DOI":"10.3390\/cells8090962"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0562","article-title":"Huntington\u2019s disease of the endocrine pancreas: Insulin deficiency and diabetes mellitus due to impaired insulin gene expression","volume":"11","author":"Andreassen","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mds.870130609","article-title":"Unified Huntington\u2019s disease rating scale: A follow up","volume":"13","author":"Siesling","year":"1998","journal-title":"Mov. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/01.wnl.0000257090.01107.2f","article-title":"Decreased frontal choline and neuropsychological performance in preclinical Huntington disease","volume":"68","author":"Alegret","year":"2007","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11892-016-0775-x","article-title":"Diabetes and cognitive impairment","volume":"16","author":"Zilliox","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"ref_45","unstructured":"(2023, September 05). FDA Center for Drug Evaluation and Research Medical Review Application Number: 021879Orig1s000, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/021879Orig1s000MedR.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0304-3959(94)90069-8","article-title":"The N-methyl-D-asparate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man","volume":"59","author":"Price","year":"1994","journal-title":"Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4140\/TCP.n.2014.264","article-title":"Dextromethorphan\/quinidine for the treatment of pseudobulbar affect","volume":"29","author":"Patatanian","year":"2014","journal-title":"Consult. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jocn.2022.04.009","article-title":"Pseudobulbar affect in neurodegenerative diseases: A systematic review and meta-analysis","volume":"100","author":"Nabizadeh","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"ref_49","unstructured":"Persaud, A., Fares, M.A., Giles, S., Gaitour, E., and Shneyder, N. (2018). Laughing and dancing: A case report of Pseudobulbar Affect in late onset Huntington\u2019s Disease. Neurology, 90, Available online: https:\/\/n.neurology.org\/content\/90\/15_Supplement\/P4.047.abstract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2018.02.006","article-title":"VMAT2 inhibitors for the treatment of tardive dyskinesia","volume":"389","author":"Scorr","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1085\/jgp.201711980","article-title":"The ins and outs of vesicular monoamine transporters","volume":"150","author":"Yaffe","year":"2018","journal-title":"J. Gen. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/bs.pmch.2017.12.002","article-title":"VMAT2 inhibitors and the path to Ingrezza (valbenazine)","volume":"57","author":"Harriott","year":"2018","journal-title":"Prog. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: A novel treatment for chorea associated with Huntington\u2019s disease","volume":"12","author":"Dean","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.36469\/9779","article-title":"Retrospective analysis of healthcare resource use, treatment patterns, and treatment-related events in patients with Huntington\u2019s Disease-associated chorea initiated on tetrabenazine","volume":"6","author":"Sung","year":"2018","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_56","unstructured":"(2023, September 20). Available online: https:\/\/www.drugs.com\/history\/austedo.html."},{"key":"ref_57","unstructured":"(2023, September 12). Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/results?cond=&term=Impact+of+Deutetrabenazine+on+Functional+Speech+and+Gait+Dynamics+in+Huntington+Disease&cntry=&state=&city=&dist=."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1044\/2015_JSLHR-S-15-0271","article-title":"Comparison of intelligibility measures for adults with Parkinson\u2019s Disease, adults with Multiple Sclerosis and healthy control","volume":"59","author":"Stipancic","year":"2016","journal-title":"J. Speech Lang. Hear. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): A phase 3, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Claassen","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Szczakowska, A., Gabryelska, A., Gawlik-Kotelnicka, O., and Strzelecki, D. (2023). Deep brain stimulation in the treatment of tardive dyskinesia. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051868"},{"key":"ref_61","unstructured":"(2023, September 13). Available online: https:\/\/www.drugs.com\/history\/ingrezza.html."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"107580","DOI":"10.1016\/j.pharmthera.2020.107580","article-title":"VMAT2 inhibitors for the treatment of hyperkinetic movement disorders","volume":"212","author":"Koch","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","article-title":"The safety of deutetrabenazine for chorea in Huntington Disease: An open-label extension study","volume":"36","author":"Frank","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_64","unstructured":"(2023, September 10). Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04400331."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington\u2019s Disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4252\/wjsc.v15.i3.31","article-title":"Clinical trials using dental stem cells: 2022 update","volume":"15","author":"Song","year":"2023","journal-title":"World J. Stem Cells"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fnins.2020.00407","article-title":"Characteristics and therapeutic potential of dental pulp stem cells on neurodegenerative diseases","volume":"14","author":"Ueda","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"654559","DOI":"10.3389\/fcell.2021.654559","article-title":"Dental-derived mesenchymal stem cells: State of the art","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wenceslau, C.V., de Souza, D.M., Mambelli-Lisboa, N.C., Ynoue, L.H., Araldi, R.P., da Silva, J.M., Pagani, E., Haddad, M.S., and Kerkis, I. (2022). Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington\u2019s Disease 3-NP rat model. Cells, 11.","DOI":"10.3390\/cells11101664"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/cell.2022.0102","article-title":"The wisdom in teeth: Neuronal differentiation of dental pulp cells","volume":"25","author":"Varga","year":"2023","journal-title":"Cell Reprogram."},{"key":"ref_71","unstructured":"(2023, September 17). Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington\u2019s Patients, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04219241?term=Clinical+Extension+Study+for+Safety+and+Efficacy+Evaluation+of+Cellavita-HD+Administration+in+Huntington%E2%80%99s+Patients&draw=2&rank=1."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170267","article-title":"Pridopidine: Overview of pharmacology and rationale for its use in Huntington\u2019s Disease","volume":"7","author":"Waters","year":"2018","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00259-020-05030-3","article-title":"Sigma-1 and dopamine D2\/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: A [18F] fluspidine and [18F] fallypride PET study","volume":"48","author":"Grachev","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_75","unstructured":"(2023, September 17). What is Pridopidine?. Available online: https:\/\/www.Prilenia.com."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","article-title":"Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor","volume":"129","author":"Eddings","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): A phase 2, randomized, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: Lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_79","unstructured":"(2023, September 15). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04556656."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1021\/acs.jmedchem.2c00313","article-title":"SAGE-718: A first-in-class N-methyl-d-aspartate receptor positive allosteric modulator for the potential treatment of cognitive impairment","volume":"65","author":"Hill","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","article-title":"Plasma 24S-hydroxycholeteral correlation with markers of Huntington disease progression","volume":"55","author":"Leoni","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14802\/jmd.21006","article-title":"Gene therapy for Huntington\u2019s disease: The final strategy for a cure?","volume":"15","author":"Byun","year":"2022","journal-title":"J. Mov. Disord."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/mds.27782","article-title":"Antisense therapies for movement disorders","volume":"34","author":"Scoles","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_86","unstructured":"(2023, September 18). Available online: https:\/\/www.clinicaltrialsarena.com\/comment\/roche-tominersen-huntingtons-asset\/?cf-view."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1515\/revneuro-2019-0072","article-title":"Could metformin be therapeutically useful in Huntington\u2019s disease?","volume":"31","author":"Tang","year":"2020","journal-title":"Rev. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Russell, R.D., Black, L.J., and Begley, A. (2022). Nutrition education programs for adults with neurological diseases are lacking: A scoping review. Nutrients, 14.","DOI":"10.3390\/nu14081577"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1212\/WNL.0b013e3181b04aa2","article-title":"Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS research participants","volume":"73","author":"Marder","year":"2009","journal-title":"Neurology"},{"key":"ref_91","unstructured":"(2023, October 11). Available online: https:\/\/hdsa.org\/find-help\/living-well-with-hd\/nutrition\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2174\/1871527320666211119122150","article-title":"Role of vitamins in neurodegenerative diseases: A review","volume":"21","author":"Kumar","year":"2022","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_93","unstructured":"(2023, October 11). Available online: https:\/\/hdsa.org\/wp-content\/uploads\/2015\/02\/11695.pdf."},{"key":"ref_94","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium (2015). Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell, 162, 516\u2013526."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s13311-019-00768-7","article-title":"DNA damage repair in Huntington\u2019s Disease and other neurodegenerative diseases","volume":"16","author":"Maiuri","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12640-018-9989-9","article-title":"Protective effects of antioxidants in Huntington\u2019s Disease: An extensive review","volume":"35","author":"Essa","year":"2019","journal-title":"Neurotox. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1038\/s41598-019-42892-6","article-title":"Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs","volume":"9","author":"Gioia","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:10:59Z","timestamp":1760130659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/11\/1513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":98,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ph16111513"],"URL":"https:\/\/doi.org\/10.3390\/ph16111513","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}